Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신수민 | * |
dc.date.accessioned | 2022-07-14T16:30:04Z | - |
dc.date.available | 2022-07-14T16:30:04Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1869-4101 | * |
dc.identifier.other | OAK-31685 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/261492 | - |
dc.description.abstract | Objectives: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. Methods: We retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0–25%; 3, 25–50%; 4, 50–75%; 5, 75–100%; and 6, 100%). Results: Pathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75–100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58–9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45–12.72) were independent prognostic factors for DFS, regardless of tumor size. Conclusion: We demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC. © 2022, The Author(s). | * |
dc.language | English | * |
dc.publisher | Springer Science and Business Media Deutschland GmbH | * |
dc.subject | Consolidation-to-tumor ratio | * |
dc.subject | Ground-glass opacity | * |
dc.subject | Lung cancer | * |
dc.subject | Prognosis | * |
dc.title | Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 13 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Insights into Imaging | * |
dc.identifier.doi | 10.1186/s13244-022-01235-2 | * |
dc.identifier.wosid | WOS:000812508300001 | * |
dc.identifier.scopusid | 2-s2.0-85132106098 | * |
dc.author.google | Yoon D.W. | * |
dc.author.google | Kim C.H. | * |
dc.author.google | Hwang S. | * |
dc.author.google | Choi Y.-L. | * |
dc.author.google | Cho J.H. | * |
dc.author.google | Kim H.K. | * |
dc.author.google | Choi Y.S. | * |
dc.author.google | Kim J. | * |
dc.author.google | Shim Y.M. | * |
dc.author.google | Shin S. | * |
dc.author.google | Lee H.Y. | * |
dc.contributor.scopusid | 신수민(55154397000) | * |
dc.date.modifydate | 20240315141520 | * |